Keywords: genentech, posts, hike, non-gapp, eps, avastin, sales

Genentech posts 53% hike in non-GAPP EPS; Avastin sales rocket, but disappoint

Article | 18 April 2005

Print This

Leading US biotechnology group Genentech presented a very solid set of first-quarter 2005 financial results, with sales of its cancer drugs ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in